FIBROKINASE INHIBITOR PROGRAM
ANG-3070 is a rationally designed, orally bioavailable small molecule fibrokinase inhibitor in advanced preclinical development for treatment of chronic kidney disease, including FSGS. ANG-3070 has exhibited preferential activity against molecular pathways involved in and associated with poor outcomes of renal fibrosis. Preclinical data in a range of glomerulosclerosis models have demonstrated therapeutic activity with decreased renal scarring. ANG-3070 is currently in development as a precision medicine for FSGS, targeting patients most likely to benefit from treatment via a biomarker driven approach.
ROCK2 INHIBITOR PROGRAM
Angion’s orally bioavailable and highly selective ROCK2 inhibitors prevent renal scarring or fibrosis. ANG-4201 has shown promising ant-fibrotic effects in preclinical animal models of kidney diseases.